Cancer Genetics And Roche To Expand Molecular Diagnostic Cancer Testing

(RTTNews) - Cancer Genetics Inc. (CGIX) and Roche Servicios S.A., an affiliate of Swiss pharmaceutical giant Roche Holding AG (RHHBY.PK), have reached an exclusive multi-year agreement to expand molecular diagnostic cancer testing in Central America and the Caribbean, Cancer Genetics said.

As per the terms of the three-year contract agreement, Cancer Genetics will leverage the power of Roche's FDA-approved cobas platform as the Company seeks to become a center of excellence for oncology-focused testing in the region. Roche's cobas technology allows for the amplification and sequencing of targeted genomic regions of interest, using mutational status to guide appropriate treatment selection.

In addition, under the agreement, Cancer Genetics will be the exclusive provider of molecular diagnostic cancer testing for Roche Servicios in Central America and the Caribbean. This expanded relationship covers multiple disease categories, including testing for lung cancer, breast cancer, and lymphoma. Cancer Genetics first began offering such testing for Roche Servicios in late 2012.

Cancer Genetics stated that it will initially focus on cobas-based testing starting with the FDA-approved epidermal growth factor receptor or EGRF mutation test, intended to help select non-small cell lung cancer patients for treatment with EGFR inhibitors. The partnership allows for expansion into other cancer categories and regions as mutually decided by Cancer Genetics and Roche.